Acumen Pharmaceuticals, Inc. Financials
This page shows Acumen Pharmaceuticals, Inc. (ABOS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Acumen Pharmaceuticals, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Acumen Pharmaceuticals, Inc. generates $0.95 in operating cash flow (-$115.5M OCF vs -$121.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Acumen Pharmaceuticals, Inc. earns $-29.4 in operating income for every $1 of interest expense (-$123.8M vs $4.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Acumen Pharmaceuticals, Inc.'s EBITDA was -$123.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 8.6% from the prior year.
Acumen Pharmaceuticals, Inc. reported -$121.3M in net income in fiscal year 2025. This represents a decrease of 18.6% from the prior year.
Acumen Pharmaceuticals, Inc. earned $-2.00 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 17.0% from the prior year.
Cash & Balance Sheet
Acumen Pharmaceuticals, Inc. generated -$115.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 34.1% from the prior year.
Acumen Pharmaceuticals, Inc. held $54.0M in cash against $22.4M in long-term debt as of fiscal year 2025.
Acumen Pharmaceuticals, Inc. had 72M shares outstanding in fiscal year 2025. This represents an increase of 20.2% from the prior year.
Margins & Returns
Acumen Pharmaceuticals, Inc.'s ROE was -172.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 116.0 percentage points from the prior year.
Capital Allocation
Acumen Pharmaceuticals, Inc. invested $104.9M in research and development in fiscal year 2025. This represents an increase of 11.8% from the prior year.
Acumen Pharmaceuticals, Inc. invested $88K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 450.0% from the prior year.
ABOS Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $22.0M-40.8% | $37.1M+46.9% | $25.3M | N/A | $27.2M+39.5% | $19.5M+56.9% | $12.4M | N/A |
| SG&A Expenses | $4.5M-1.7% | $4.6M-9.4% | $5.1M | N/A | $5.0M+3.5% | $4.8M-9.0% | $5.3M | N/A |
| Operating Income | -$26.5M+36.5% | -$41.8M-37.5% | -$30.4M | N/A | -$32.3M-32.3% | -$24.4M-37.2% | -$17.8M | N/A |
| Interest Expense | $1.1M+2.1% | $1.0M+2.2% | $1.0M | N/A | $1.0M+2.3% | $1.0M+0.4% | $1.0M | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$26.5M+35.4% | -$41.0M-42.2% | -$28.8M | N/A | -$29.8M-44.9% | -$20.5M-38.1% | -$14.9M | N/A |
| EPS (Diluted) | $-0.44+35.3% | $-0.68-41.7% | $-0.48 | N/A | $-0.50-47.1% | $-0.34-36.0% | $-0.25 | N/A |
ABOS Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $142.2M-17.3% | $171.9M-15.9% | $204.5M-14.4% | $239.0M-10.5% | $267.0M-7.6% | $288.9M-4.0% | $301.0M-3.0% | $310.1M |
| Current Assets | $132.2M-11.0% | $148.4M-4.2% | $154.9M-13.1% | $178.3M-14.1% | $207.6M-22.2% | $266.9M+4.3% | $255.8M+3.7% | $246.6M |
| Cash & Equivalents | $46.8M+27.2% | $36.8M+22.1% | $30.2M-15.3% | $35.6M+7.4% | $33.2M-51.2% | $68.0M+44.8% | $46.9M-29.8% | $66.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $49.0M-10.5% | $54.8M+12.0% | $49.0M-14.4% | $57.2M+14.9% | $49.8M+10.7% | $45.0M+15.5% | $38.9M-9.8% | $43.2M |
| Current Liabilities | $22.0M-11.7% | $24.9M+28.7% | $19.3M-30.0% | $27.6M+38.6% | $19.9M+29.6% | $15.4M+81.4% | $8.5M-34.7% | $13.0M |
| Long-Term Debt | $27.1M-9.5% | $29.9M+1.2% | $29.5M+0.4% | $29.4M-0.9% | $29.7M+1.0% | $29.4M-2.7% | $30.2M+1.0% | $29.9M |
| Total Equity | $93.2M-20.4% | $117.1M-24.7% | $155.5M-14.5% | $181.8M-16.3% | $217.2M-11.0% | $243.9M-6.9% | $262.0M-1.8% | $267.0M |
| Retained Earnings | -$421.3M-6.7% | -$394.9M-11.6% | -$353.9M-8.9% | -$325.1M-12.9% | -$288.0M-11.5% | -$258.2M-8.6% | -$237.7M-6.7% | -$222.8M |
ABOS Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$30.5M+4.2% | -$31.8M+6.7% | -$34.1M-25.4% | -$27.2M-10.6% | -$24.6M-48.7% | -$16.5M+7.4% | -$17.9M-114.8% | -$8.3M |
| Capital Expenditures | $0-100.0% | $9K-88.6% | $79K | $0 | $0-100.0% | $5K-54.5% | $11K-21.4% | $14K |
| Free Cash Flow | -$30.5M+4.2% | -$31.8M+6.9% | -$34.2M-25.7% | -$27.2M-10.6% | -$24.6M-48.6% | -$16.6M+7.4% | -$17.9M-114.6% | -$8.3M |
| Investing Cash Flow | $40.5M+5.3% | $38.5M+34.1% | $28.7M-3.3% | $29.7M+392.8% | -$10.1M-126.9% | $37.7M+509.6% | -$9.2M+81.1% | -$48.8M |
| Financing Cash Flow | $0 | $0+100.0% | -$36K-300.0% | -$9K+78.6% | -$42K+67.2% | -$128K-101.8% | $7.1M-75.6% | $29.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ABOS Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -28.4%+6.6pp | -35.0%-16.5pp | -18.5% | N/A | -13.7%-5.3pp | -8.4%-2.7pp | -5.7% | N/A |
| Return on Assets | -18.6%+5.2pp | -23.8%-9.7pp | -14.1% | N/A | -11.2%-4.0pp | -7.1%-2.2pp | -4.9% | N/A |
| Current Ratio | 6.02+0.0 | 5.97-2.1 | 8.02+1.6 | 6.46-4.0 | 10.43-6.9 | 17.37-12.8 | 30.20+11.2 | 19.01 |
| Debt-to-Equity | 0.29+0.0 | 0.26+0.1 | 0.19+0.0 | 0.16+0.0 | 0.14+0.0 | 0.120.0 | 0.120.0 | 0.11 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Acumen Pharmaceuticals, Inc. profitable?
No, Acumen Pharmaceuticals, Inc. (ABOS) reported a net income of -$121.3M in fiscal year 2025.
What is Acumen Pharmaceuticals, Inc.'s EBITDA?
Acumen Pharmaceuticals, Inc. (ABOS) had EBITDA of -$123.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Acumen Pharmaceuticals, Inc. have?
As of fiscal year 2025, Acumen Pharmaceuticals, Inc. (ABOS) had $54.0M in cash and equivalents against $22.4M in long-term debt.
What is Acumen Pharmaceuticals, Inc.'s return on equity (ROE)?
Acumen Pharmaceuticals, Inc. (ABOS) has a return on equity of -172.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Acumen Pharmaceuticals, Inc.'s free cash flow?
Acumen Pharmaceuticals, Inc. (ABOS) generated -$115.6M in free cash flow during fiscal year 2025. This represents a -34.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Acumen Pharmaceuticals, Inc.'s operating cash flow?
Acumen Pharmaceuticals, Inc. (ABOS) generated -$115.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Acumen Pharmaceuticals, Inc.'s total assets?
Acumen Pharmaceuticals, Inc. (ABOS) had $122.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Acumen Pharmaceuticals, Inc.'s capital expenditures?
Acumen Pharmaceuticals, Inc. (ABOS) invested $88K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Acumen Pharmaceuticals, Inc. spend on research and development?
Acumen Pharmaceuticals, Inc. (ABOS) invested $104.9M in research and development during fiscal year 2025.
What is Acumen Pharmaceuticals, Inc.'s current ratio?
Acumen Pharmaceuticals, Inc. (ABOS) had a current ratio of 4.07 as of fiscal year 2025, which is generally considered healthy.
What is Acumen Pharmaceuticals, Inc.'s debt-to-equity ratio?
Acumen Pharmaceuticals, Inc. (ABOS) had a debt-to-equity ratio of 0.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Acumen Pharmaceuticals, Inc.'s return on assets (ROA)?
Acumen Pharmaceuticals, Inc. (ABOS) had a return on assets of -98.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Acumen Pharmaceuticals, Inc.'s cash runway?
Based on fiscal year 2025 data, Acumen Pharmaceuticals, Inc. (ABOS) had $54.0M in cash against an annual operating cash burn of $115.5M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Acumen Pharmaceuticals, Inc.'s Piotroski F-Score?
Acumen Pharmaceuticals, Inc. (ABOS) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Acumen Pharmaceuticals, Inc.'s earnings high quality?
Acumen Pharmaceuticals, Inc. (ABOS) has an earnings quality ratio of 0.95x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Acumen Pharmaceuticals, Inc. cover its interest payments?
Acumen Pharmaceuticals, Inc. (ABOS) has an interest coverage ratio of -29.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.